cbd and heart failure

December 15, 2021 By admin Off

Because of the high sugar content, you should avoid CBD edibles if you have diabetes or are struggling with obesity.

CBD is renowned for its anti-inflammatory benefits. This desirable trait could help prevent heart failure in the long term.

So, what are the potential benefits of CBD for congestive heart failure?

High blood pressure, also known as hypertension, is where your blood pressure is higher than normal.

When looking for the best CBD product for your condition, we advise you to research the brand and check the independent lab reports. This way, you’ll be certain you’re receiving the best possible treatment.

CBD Edibles.

Although they’re great if you’re suffering from a skin condition, they pose no real value for conditions that are related to heart failure.

In the United States, around 655,000 people die each year from heart failure.

When the body has a lack of insulin or the insulin present isn’t functioning as it should, glucose can build up in the bloodstream. Over time, the excess glucose, if left untreated, can cause serious health issues including eventual heart failure.

Edibles are fantastic if you can’t stand the taste of raw CBD oil. However, they’re not ideal for treating some conditions related to congestive heart failure.

Although the cannabinoid THC seems to regulate blood sugar more effectively than CBD, full-spectrum oil may have the same desired effect.

Congestive heart failure, also known simply as heart failure, occurs when the heart cannot pump enough blood around the body.

Capsules provide you with an accurate dosage per capsule and medicating is as easy as swallowing a pill.

It’s important to note that these symptoms do match up with other conditions and are considered normal in some circumstances.

Don’t overthink if you’re experiencing one or two of these symptoms mildly, but make sure to check with your doctor if you’re concerned about your heart health. It’s better to be safe than sorry.

Congestive heart failure happens after many years of blocked arteries, high blood pressure, or damaged chambers. This can be caused by a number of different health issues, the main of which are listed above.

4. CBD Lowers Blood Pressure.

CBD isolate is a pure extract of the cannabinoid CBD (cannabidiol). Oils, edibles, and topicals that are made using isolate contain only CBD with no other cannabinoids or terpenes present.

The right dosage for one person won’t be correct for another, so there is some level of self-experimentation needed to find out what’s right for you.

CBD works differently from person to person.

CBD capsules are a great option for congestive heart failure because they contain no sugar and are relatively bioavailable.

As with most things, prevention is better than a cure. CBD isn’t the cure for congestive heart failure, but studies suggest it may help prevent it.

You’re considered obese when your BMI is over 30.

Unfortunately, there’s little known about the negative effects of vaping CBD, so if you’re suffering from a severe health condition it isn’t the first consumption method you should look at.

2. CBD Helps to Fight Obesity.

This type of CBD is the most valuable to use for multiple health conditions and holds the most potential for preventing congestive heart failure. This is because it provides the full entourage effect.

Put simply, diabetes affects how your body processes food into energy. It’s a chronic health condition that can be treated and controlled but has no cure.

There are many ways to consume CBD. Some are better than others for treating conditions that are associated with congestive heart failure. It’s important to know which products are best.

The higher your blood pressure, the more risk you face for other conditions and health issues. Left untreated, high blood pressure can lead to heart disease, stroke, or a heart attack.

As mentioned, CBD alone isn’t going to prevent heart failure, but it can be used to treat some conditions that could lead to it.

CBD can aid in weight loss.

How you use CBD for congestive heart failure will affect the results you get. Choosing the right CBD product is vital to reaping the rewards that this cannabinoid sows.

CBD oil provides you with the most flexibility in terms of dosage. It’s also one of the best ways to consume CBD for heart failure because it’s highly bioavailable and has few additives that will trigger any undesirable effects.

Tinnakorn Jorruang / Getty Images.

A growing body of evidence shows that dysregulated ECS is associated with a number of cardiovascular diseases. Whether you have a heart condition or want to prevent heart disease, CBD may boost your endocannabinoid system to help it regulate the cardiovascular system.

This interference may prevent the liver from metabolizing other medications as it normally would, leading to higher concentrations of the medication in the body and increasing the risk of liver toxicity.

Overview of Heart Failure.

The availability of these products varies from state to state, particularly for products that contain THC.

Heart disease is an umbrella term that refers to several types of heart conditions. Heart disease may involve the heart valves, arteries, and heart rate, leading to heart failure.

Cannabidiol comes in several forms and methods of application. People with heart disease should avoid products that require vaping or smoking.

Both CBD and THC interact with the endocannabinoid system (ECS) in the body. The ECS is a complex biological system that impacts many of the body’s functions, including appetite, memory, mood, and sleep. Researchers are learning that the endocannabinoid plays a role in the function of the cardiovascular (heart) system.

While more research is needed to be sure, CBD may be helpful in lowering blood pressure to prevent congestive heart failure.

With so many CBD options available, shopping for the right product can be an overwhelming experience. Some important things to keep in mind when buying CBD include:

CBD and Heart Health.

Research suggests that even a single dose of CBD can lower blood pressure. High blood pressure has been linked to congestive heart failure. This is because high blood pressure makes it more difficult for blood to travel easily throughout the body, causing the heart to work harder.

CBD has significant potential to treat a variety of heart diseases and comes with few adverse side effects, though more research is needed. Talk with your doctor before using CBD for heart disease, particularly if you are currently taking any other medications.

Heart failure has a number of causes, including genetics, other medical conditions (e.g., anemia, diabetes, sleep apnea), and lifestyle (e.g., smoking, obesity).

CBD cannot cure heart disease or congestive heart failure, but it is being studied for ways it may help reduce symptoms or prevent heart disease. However, CBD has not been shown in large studies to prevent diseases that lead to heart failure.

How to Buy CBD.

One study found that CBD has a direct effect on the arteries, helping reduce inflammation and improving blood flow. This suggests that CBD reduces inflammation in arteries and blood vessels, easing the strain on the heart, potentially preventing heart failure.

With heart failure, the heart cannot supply the body’s cells with enough blood, leading to symptoms that can have a tremendous impact on your quality of life.

If you are currently taking any other medications, speak with your doctor before trying CBD. Some research suggests that CBD may interfere with the way the liver processes certain medications.

CBD has few side effects, and the World Health Organization states that it is generally well tolerated and has a good safety profile. While relatively safe, there are a few things to consider before you try CBD.

While CBD is not a cure for heart failure, it may prevent further damage thanks to its anti-inflammatory properties. CBD may be helpful in reducing blood pressure, decreasing inflammation and cholesterol, and maintaining a healthy weight. Improving these factors may reduce the risk of heart failure.

Cardiol’s President and CEO, David Elsley, previously founded Vasogen Inc. in the 1990’s. Vasogen was a biotech focused on treating heart conditions and inflammatory disease, and under Mr. Elsley’s watch it went public on the NASDAQ and the TSX, reaching a market capitalization north of US$1 billion. His experience in founding and growing a company from start-up through clinical trials is essential as he guides Cardiol Therapeutics through a similar growth process.

For Cannabis Businesses & Companies.

Please follow the link to read the full article: https://www.cannabisfn.com/heart-failure-and-cbd/

There are two main types of HF: heart failure with poor contraction or reduced ejection fraction (HFrEF), also known as systolic heart failure, and heart failure with poor relaxation or preserved ejection fraction (HFpEF), also known as diastolic heart failure. About half of HF patients suffer from HFpEF. Unfortunately, treatment for HFpEF has not advanced over the last couple of decades, with the standard of care currently involving the use of diuretics such as Lasix to relieve swelling of the tissue by removing water and salt. Diuretics do improve symptoms but there is a lack of data indicating that diuretics are actually effective in the treatment of the causes of HF.

The company has partnered with TecSalud del Tecnológico de Monterrey (“TecSalud”) in Mexico in a US$3 million R&D program. TecSalud has collaborative relationships with the DeBakey Heart & Vascular Center and the Massachusetts Institute of Technology for its nanotechnology programs.

About CFN Media.

Cardiol is collaborating with researchers and opinion leaders at international centers of excellence to leverage multidisciplinary expertise in drug delivery, drug formulation, nanotherapeutics, cardiac physiology, and heart failure to advance its clinical programs. The company’s nanotechnology is developed in conjunction with the National Institute for Nanotechnology, a joint venture of the University of Alberta, the National Research Council of Canada, and the Government of Alberta.

The company is also collaborating with the DeBakey Heart & Vascular Center in Houston, one of the leading heart hospitals in the United States, to investigate its nanotechnology as it relates directly to treatment of heart failure.

There is great upside potential for Cardiol as the company advances its therapies for the treatment of HF. Concurrently, the company is advancing its immunotherapeutic for the treatment of GBM, the most frequent and deadliest form of cancer affecting the brain. Treatments in the US for GBM are eligible for orphan drug status, meaning clinical research is subject to Fast Track review, with the intent of getting successful treatments to market as quickly as possible.

Nanotechnology Enables Targeted CBD Delivery.

After going public with an IPO on the Toronto Stock Exchange on December 20, 2018, Cardiol Therapeutics is looking forward to an eventful 2019. The company is introducing ultra-pure pharmaceutical CBD to a Canadian medical market that is currently experiencing a major supply shortfall following the full legalization of cannabis. Cardiol views this as a significant revenue opportunity, and it serves as a major differentiator when compared to other biotech companies exclusively involved in clinical research. In lockstep, Cardiol expects to advance its product pipeline, specifically, its CBD-based HF treatment.

For Visitors and Viewers.

Heart failure (HF) affects more than 6 million adults in Canada and the United States and is a leading cause of hospitalization, with costs exceeding $30 billion each year in the US alone. People with HF suffer from shortness of breath, rapid heart rate, edema, reduced exercise capacity, often struggle with simple daily activities, and are frequently hospitalized. For many, these symptoms significantly reduce quality of life.

There are several potential milestones and catalysts for CRDL over the coming months. Combining the proven value creation of biotech drug development with the explosive potential of cannabinoid-based therapies, while targeting an enormous heart failure market, Cardiol Therapeutics is well positioned for significant growth.

Overall, Cardiol is collaborating with some of the world’s best heart and nanotech research organizations to develop its diverse product pipeline.

He is joined by many other proven industry leaders, including the company’s Chief Medical Officer, Dr. Eldon Smith. Dr. Smith is the former Head of Cardiology and Dean of Medicine at the University of Calgary. He also spent 14 years as Editor-in-Chief of the Canadian Journal of Cardiology. Dr. Smith has served on a wide variety of medical societies and associations, both in the private and public sector. He also brings a wealth of public company experience to Cardiol, having served as Director of more than ten public companies.

Cardiol has developed a unique patented system whereby lipophilic (fat soluble) drugs like CBD, are encased in a hydrophilic (water soluble) shell. This shell allows the active lipophilic ingredient to effectively circulate in the bloodstream. Normally, taking CBD orally results in less than 10% bioavailability, due to “first-pass” metabolism by the liver. Cardiol’s nanotherapeutics delivery methodology, which avoids the oral route, allows for much higher levels of lipophilic active ingredients in the bloodstream and, most importantly, has the potential to deliver drugs to specific sites of inflammation in the body. This proprietary technology could be licensed or partnered with other companies. Furthermore, the opportunity here is not just limited to CBD delivery, as these same problems have vexed companies developing other lipophilic drugs.

2019 a Pivotal Year for Cardiol.

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

By utilizing this nanotechnology delivery system, Cardiol has found in an experimental model that its nanoparticles preferentially accumulate in inflamed heart tissue. These findings validate the platform’s targeted delivery and point the way to further research through a clinical trial program.

Collectively, Cardiol’s executive team has extensive scientific, regulatory, and public company experience. This leadership is essential to the company’s development and potential for success, as it navigates the complexities of bringing HF drug candidates through the clinical trial process to potential commercialization.